Abstract

https://ssrn.com/abstract=2373497
 


 



Median Survival, Hazard Ratios and Bounding Drug Effectiveness


Christopher Adams


Federal Trade Commission - Bureau of Economics

December 31, 2013


Abstract:     
This paper shows that differences in median survival rates are not be informative of a drug's effectiveness. The existence or lack of existence of a difference does not inform public policy or patient decision making. Moreover, other commonly used summary measures such as Kaplan-Meier plots and hazard ratios are generally not informative either. Published results from the EMILIA trial show that median survival difference was 5.8 months and the hazard ratio was statistically significantly less than 1 for T-DM1 against the benchmark. The FDA approved T-DM1 for metastatic breast cancer treatment based upon these results. However, without strong and non-credible assumptions we can only say that at least 7% of the sampled population would live longer on T-DM1 relative to the benchmark and some positive proportion of patients who would live 6 months longer on T-DM1 relative to the benchmark. The presented results do not allow us to rule out the possibility that most of the sampled population would live longer on the benchmark than on T-DM1.

Number of Pages in PDF File: 21

Keywords: treatment effect, median survival, bounds

JEL Classification: C34, C90, I12, I18


Open PDF in Browser Download This Paper

Date posted: January 2, 2014  

Suggested Citation

Adams, Christopher, Median Survival, Hazard Ratios and Bounding Drug Effectiveness (December 31, 2013). Available at SSRN: https://ssrn.com/abstract=2373497 or http://dx.doi.org/10.2139/ssrn.2373497

Contact Information

Christopher Adams (Contact Author)
Federal Trade Commission - Bureau of Economics ( email )
601 Pennsylvania Avenue, NW
Rm. 4210
Washington, DC 20580
United States
202-326-2592 (Phone)
202-326-3443 (Fax)
Feedback to SSRN


Paper statistics
Abstract Views: 259
Downloads: 33